scholarly journals Nocturnal polyuria in men performing uroflowmetry for lower urinary tract symptoms

2021 ◽  
Vol 93 (4) ◽  
pp. 445-449
Author(s):  
Emanuele Rubilotta ◽  
Daniele Castellani ◽  
Marilena Gubbiotti ◽  
Matteo Balzarro ◽  
Giacomo Maria Pirola ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Nocturnal Polyuria ◽  
Voiding Symptoms ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
The Impact ◽  
Lower Urinary

Purpose: To assess the prevalence of nocturnal polyuria (NP) in males performing uroflowmetry (UF) for lower urinary tract symptoms (LUTS), the impact of NP on UF outcomes, and bladder emptying, the association between NP and LUTS. Materials and methods: Men scheduled for UF were recruited in two Centres. Data collected were medical history, IPSS, UF, post-void residual urine volume (PVR), 3-day frequency-volume charts (FVC). The NP index was used to assess NP with a threshold of ≥ 33%. The relationship between NP and patient’s aging was assessed. Results: 162 patients were included in the analysis. Mean age was 70.95 ± 8.04 years. The prevalence of NP was 54.9% (89/162). 110 (68%) patients reported nocturia, and among these, NP was documented in 76 (69%). Nocturia was found in 85% (76/89) of the population with NP. Total IPSS score, IPSS items #1, #2 and #7 showed a significant difference in men with NP compared with those without. Maximum flow rate and PVR did not significantly change comparing men with or without NP. Mean voiding volume (VV) of the night-time micturitions was significantly higher in men with NP compared to those without NP (532.1 ± 275.6 ml vs 175 ± 168.7 ml respectively, p < 0001), while mean VV day-time micturitions and mean VV at UF did not change between groups.Conclusions: NP had a high prevalence in men with LUTS performing UF. Aged males were more commonly affected by NP. Data demonstrated a strong relationship between NP and nocturia and increased urinary frequency while voiding symptoms were poorly related to NP.

scholarly journals Effect of Premicturitional Bladder Volume on the Accuracy of Sonographic Assessment of Post Void Residual Urine Volume Measurement by Transabdominal Ultrasonography

2019 ◽  
Vol 18 (1) ◽  
pp. 30-36
Author(s):  
Roshani Pathak ◽  
Sunil Pradhan ◽  
Abhushan Tuladhar ◽  
Amit Shrestha ◽  
Riwaz Acharya
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Bladder Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Lower Urinary

Introduction: The Post Void Residual Urine volume (PVRU) is frequently significant in patients with bladder outflow obstruction; especially in patients with enlarged prostate and prostatism. The PVRU forms an important part of radiological investigation. Accurate measurement of the residual urine volume changes observed serially over a period of time may indicate clinical progress. The purpose of this study was to evaluate the effect of pre-void bladder volume on PVRU measurements. Methods: A prospective study was conducted to determine the accuracy of PVRU measurement in patient presenting with lower urinary tract symptoms (LUTS). 50 patients with LUTS were assessed ultrasonographically for pre void and post void bladder volumes during the study period of March 2017 till August 2017. PVRU measurements done in patients with bladder filling sensation at moderate to full capacity resulted in high estimations of PVRU which was quite significant in this study. Results: There was significant difference in the estimated PVRU between patients having high initial premicturitional volume (546±144 ml) than those with lower or moderate filling volume (261±58 ml) with mean of 173 ml and 35 ml respectively. The difference in estimated PVRU was highly significant with p value of < 0.0001. Conclusions: Measurement of pre void urinary bladder volume with an uncomfortably full bladder results in high post micturitional (PMRU) values even in most patients without lower urinary tract symptoms which may be false-positive. We advise that initial or pre-void urine volume be measured when the patient has initial or moderate feeling of bladder fullness.  

scholarly journals Effect of Calcium Channel Blockers on Lower Urinary Tract Symptoms: A Systematic Review

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Muhammad Salman ◽  
Amer Hayat Khan ◽  
Syed Azhar Syed Sulaiman ◽  
Junaid Habib Khan ◽  
Khalid Hussain ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Calcium Channel ◽  
Lower Urinary Tract Symptoms ◽  
Calcium Channel Blockers ◽  
Lower Urinary Tract ◽  
Channel Blockers ◽  
Inverse Association ◽  
Voiding Symptoms ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Background. Numerous medications are known to be associated with the development of lower urinary tract symptoms (LUTS). One such medication group is calcium channel blockers (CCB). Objective. To critically examine the literature regarding the involvement of CCB in manifestation of LUTS in humans. Methods. A systematic literature search was conducted on PubMed, SciELO, Scopus, and OpenGrey databases to find all potentially relevant research studies before August 2016. Results. Five studies met the inclusion criteria and were included in this review. Three out of five studies stated that CCB were involved in either precipitation or exacerbation of LUTS. As for the remaining two studies, one study found out that only the monotherapy of CCB was associated with increased prevalence of nocturia and voiding symptoms in young females, whereas the other study reported an inverse association of CCB with LUTS. The methodological quality of studies was considered high for four studies and low for one study. Conclusion. Healthcare providers should make efforts for an earlier identification of the individuals at risk of LUTS prior to the commencement of CCB therapy. Moreover, patients should be counselled to notify their healthcare provider if they notice urinary symptoms after the initiation of CCB.

scholarly journals Population-Based Study of Prevalence, Bother and Behavior Related to Treatment for Lower Urinary Tract Symptoms and Overactive Bladder among Polish Neurogenic Patients

2021 ◽  
Vol 11 (6) ◽  
pp. 712
Author(s):  
Mikolaj Przydacz ◽  
Marcin Chlosta ◽  
Tomasz Golabek ◽  
Piotr Chlosta
Keyword(s):  
Urinary Tract ◽  
Overactive Bladder ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Population Level ◽  
Computer Assisted ◽  
Voiding Symptoms ◽  
Urinary Tract Symptoms ◽  
And Behavior ◽  
Lower Urinary

Background: The aim of this study was to perform a cross-sectional study of Polish neurogenic patients to measure, at the population level, the prevalence, bother and behavior associated with treatment for lower urinary tract symptoms (LUTS) and overactive bladder (OAB). Methods: This epidemiological study was based on data from LUTS POLAND, a computer-assisted and population-representative telephone survey. Participants were classified by age, sex and place of residence. Results: LUTS POLAND includes 6005 completed interviews, of which 1166 (19.4%) were for individuals who had ever received any treatment by neurologists and/or neurosurgeons. Among these neurogenic participants, LUTS prevalence was 72.3%, statistically higher than for non-neurogenic respondents. At the population level, neurogenic patients had about a 20% higher risk for LUTS presence than non-neurogenic participants (relative risk: 1.17–1.21). LUTS prevalence did not differ between men and women. Frequency was the most common of the LUTS. Forty percent of neurogenic respondents described having more than one LUTS subtype (i.e., storage, voiding, and/or post-micturition symptom subtype), and more than 50% of respondents reported OAB symptoms. Both storage and voiding symptoms were bothersome, and many neurogenic individuals (42.3–51.0%) expressed anxiety about bladder function affecting quality of life. Only one-third (34.9–36.6%) of neurogenic participants had sought treatment for their LUTS, and the majority of such individuals received and maintained treatment. Conclusions: LUTS and OAB symptoms were highly prevalent and bothersome among Polish neurogenic patients at the population level. Because the scale of seeking treatment for LUTS was low, Polish neurogenic patients may not be adequately informed about multiple effects of LUTS and OAB.

Possibilities of phytotherapy in patients with lower urinary tract symptoms due to benign prostate enlargement

2020 ◽  
Vol 10 (4) ◽  
pp. 317-323
Author(s):  
Adel S. Al-Shukri ◽  
Stanislav V. Kostyukov
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostate Gland ◽  
Urine Volume ◽  
Good Tolerability ◽  
Clinical Indicators ◽  
Urinary Tract Symptoms ◽  
Main Component ◽  
Lower Urinary

The results of the use of the phytopreparation Tadimax in the treatment of 60 men with mild and moderate lower urinary tract symptoms (LUTS) developed as a result of benign enlargement of the prostate gland are presented. The average age of the patients was 66.5 3.8 years. Tadimax was prescribed 2 tablets 3 times a day, in courses of 7 days with 7 day breaks for 3 months (a total of 6 courses). The data obtained indicate high efficacy and good tolerability of treatment. A decrease in the severity of LUTS was noted in 59 (96.6%) patients, which was accompanied by significant changes in objective clinical indicators: a decrease in residual urine volume and an increase in urine flow rate. Tadimax is a combined preparation, which includes extracts of several medicinal plants, and the main component is Crinum latifolium. The therapeutic effect of Tadimax is based on anti-inflammatory, antiproliferative and immunotropic action.

scholarly journals The reliability and reproducibility of ultrasonography for measuring the residual urine volume in men with lower urinary tract symptoms

2014 ◽  
Vol 12 (4) ◽  
pp. 285-289 ◽  
Author(s):  
Hassan A. Abdelwahab ◽  
Housseini M. Abdalla ◽  
Mahmoud H. Sherief ◽  
Mohamed B. Ibrahim ◽  
Mostafa A. Shamaa
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Surveying the Prevalence of Lower Urinary Tract Symptoms Based on Individual and Clinical Parameters in Patients with Multiple Sclerosis

2019 ◽  
Author(s):  
Fatemeh Nazari ◽  
Vahid Shaygannejad ◽  
Mehrdad Mohammadi Sichani ◽  
Marjan Mansourian Gharaagozlou ◽  
Valiollah Hajhashemi
Keyword(s):  
Multiple Sclerosis ◽  
Urinary Tract ◽  
Symptom Score ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Statistical Tests ◽  
Men And Women ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Lower Urinary

Abstract Background Most patients with multiple sclerosis (MS) suffer from bladder dysfunction during the course of the disease. This study was conducted to examine the prevalence of these complications among patients with MS. Methods This cross-sectional study was performed on 603 patients with MS who referred to the neurology clinics of Kashani and Alzahra Hospitals affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. The sampling was performed by multi-stage random cluster sampling method and the informed consent form was filled in by the subjects. Then, all the data were collected through interviews using the Lower Urinary Tract Symptom Score (LUTSS) developed in accordance with the definitions presented by the International Continence Society (ICS) and the International Prostate Symptom Score (I-PSS). The data were analyzed using descriptive and inferential statistical tests in SPSS and the significance level was considered to be less than 0.050. Results The prevalence rate of lower urinary tract symptoms (LUTS) was 87.6% among all the subjects, with a similar rate among women (88.0%) and men (86.0%). There was a significant difference between the two groups of men and women in terms of the prevalence of stress urinary incontinence (SUI), intermittent urine flow, hesitancy, straining, and dribbling (P < 0.050). There was no significant difference between the two groups of women and men in terms of the prevalence of other symptoms (P > 0.050). Moreover, there was a significant difference between the degree of LUTS with age, marital status, education, duration of illness, clinical course, and disability (P < 0.05). Conclusions A high prevalence of LUTS was found among patients with MS, with similar rates in men and women, and the nature of the urinary complaints and LUTS was different among men and women with MS. Therefore, it is recommended that the health system take necessary measures regarding timely detection and treatment of LUTS among these patients in order to prevent secondary outcomes and improve the quality of life (QOL) of patients with MS.

scholarly journals Prospective randomized controlled study directly comparing tadalafil and tamsulosin for male patients with lower urinary tract symptoms

2018 ◽  
Author(s):  
Takumi Takeuchi ◽  
Satoshi Toyokawa ◽  
Yumiko Okuno ◽  
Noriko Ishida ◽  
Masanari Yamagoe ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Maximum Flow ◽  
Controlled Study ◽  
Night Time ◽  
Once Daily ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

AbstractLower urinary tract symptoms are widespread in elderly men and often suggestive of benign prostatic hyperplasia (LUTS/BPH). A randomized, prospective, and open-labeled trial directly comparing the effects of tadalafil (a phosphodiesterase 5 inhibitor) 5 mg once daily and tamsulosin (an α1-blocker) 0.2 mg once daily for 12 weeks in LUTS/BPH patients was conducted. Data were recorded before randomization as well as at 4, 8, and 12 weeks after medication. Fifteen patients allocated tadalafil and 20 allocated tamsulosin completed 12 weeks of medication. Total IPSS, IPSS voiding, and IPSS-QOL scores declined with medication, but there was no difference between drugs. IPSS storage scores reduced more in the tamsulosin group than tadalafil group. OABSS did not decline significantly with medication. IIEF5 was maintained in the tadalafil group, but declined in the tamsulosin group. The maximum flow rate and post-void residual urine volume did not significantly change with medication. Daytime, night-time, and 24-hour urinary frequencies as well as the mean and largest daytime, night-time, and 24-hour voiding volumes per void did not significantly change with medication. In conclusion, tamsulosin was more effective to reduce storage symptoms than tadalafil. Tadalafil had the advantage of maintaining the erectile function.

scholarly journals Association of metabolic syndrome and lower urinary tract symptoms amongst South Indian postmenopausal women

2017 ◽  
Vol 6 (10) ◽  
pp. 4393
Author(s):  
Jeyasheela Kamaraj ◽  
Vaibhav Londhe ◽  
Sahana Shetty ◽  
Aruna Nitin Kekre ◽  
Thomas V. Paul ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Composition ◽  
Urinary Tract ◽  
Postmenopausal Women ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Whole Body ◽  
Urinary Tract Symptoms ◽  
Significant Difference ◽  
Lower Urinary

Background: Women spend one third of their life in menopause. The age related anatomical and physiological changes predispose them to MetS and lower urinary tract symptoms (LUTS). The aim was to study the prevalence of metabolic syndrome (MetS) and lower urinary tract symptoms in postmenopausal women attending menopause clinic, to study the correlation of LUTS and body composition among women with MetS.Methods: 154 post-menopausal women who attended menopause clinic at the Christian Medical College Hospital Vellore, were recruited. MetS was diagnosed using IDF criteria. LUTS were assessed BFLUTS questionnaires. Blood was taken to assess serum fasting glucose and lipid profile. DEXA was performed to assess the whole-body composition.Results: Of 154 postmenopausal women, 64% had MetS and 43% of women had a total LUTS score > 5. 90% of women had filling symptoms,57% had incontinence,17% had voiding symptoms,14 % had quality of life issues and 6 % had sexual symptoms. However, there was no statistical significant difference between two groups in correlating the variables of MetS with LUTS (P >0.05). The percentage of total body fat by DEXA scan was significantly greater (P=0.006) in women with MetS (37.32±5.04) when compared to the women without MetS (34.629±3.65).Conclusions: Prevalence of MetS among the study population was 64 %. LUTS were observed in 43% of the patients. There was no significant difference in LUTS in women with MetS and without Mets. However, there was a significant difference in body composition among women with and without MetS.

scholarly journals The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Naoya Masumori ◽  
Taiji Tsukamoto ◽  
Masahiro Yanase ◽  
Hiroki Horita ◽  
Masaharu Aoki
Keyword(s):  
Urinary Tract ◽  
Overactive Bladder ◽  
Symptom Score ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Real Life ◽  
Benign Prostatic Obstruction ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Objectives. To investigate the add-on effect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-life clinical practice.Methods. Patients aged ≥ 50 having remaining OAB symptoms (≥ 3 of OAB symptom score (OABSS) with ≥2 of urgency score) after at least 4 weeks treatment by 0.2 mg of tamsulosin for BPO/LUTS received 2.5 or 5.0 mg of solifenacin for 12 weeks. The International Prostate Symptom Score (IPSS), QOL index and OABSS, maximum flow rate (Qmax) and postvoid residual urine volume (PVR) were determined.Results. A total of 48 patients (mean age 72.5 years) completed the study. There were significant improvement in IPSS (15.1 to 11.2) and QOL index (4.2 to 3.0) by add-on of solifenacin. Although the IPSS storage symptom score was significantly improved, there were no changes observed in the IPSS voiding symptom score. The OABSS showed significant improvement (8.0 to 4.8). No changes were observed in Qmax and PVR.Conclusions. Under the supervision of an experienced urologist, the additional administration of solifenacin to patients with BPO/LUTS treated with tamsulosin, is effective in controlling remaining OAB symptoms.

Sign in / Sign up

Export Citation Format

Share Document